These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 22590614

  • 21. Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses.
    Shafique M, Meijerhof T, Wilschut J, de Haan A.
    PLoS One; 2013; 8(4):e61287. PubMed ID: 23593453
    [Abstract] [Full Text] [Related]

  • 22. Mucosal immunization with a low-energy electron inactivated respiratory syncytial virus vaccine protects mice without Th2 immune bias.
    Eberlein V, Rosencrantz S, Finkensieper J, Besecke JK, Mansuroglu Y, Kamp JC, Lange F, Dressman J, Schopf S, Hesse C, Thoma M, Fertey J, Ulbert S, Grunwald T.
    Front Immunol; 2024; 15():1382318. PubMed ID: 38646538
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses.
    Zeng R, Zhang H, Hai Y, Cui Y, Wei L, Li N, Liu J, Li C, Liu Y.
    J Virol; 2012 Apr; 86(8):4505-17. PubMed ID: 22301139
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats.
    O'Konek JJ, Makidon PE, Landers JJ, Cao Z, Malinczak CA, Pannu J, Sun J, Bitko V, Ciotti S, Hamouda T, Wojcinski ZW, Lukacs NW, Fattom A, Baker JR.
    Hum Vaccin Immunother; 2015 Apr; 11(12):2904-12. PubMed ID: 26307915
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
    Shafique M, Wilschut J, de Haan A.
    Vaccine; 2012 Jan 11; 30(3):597-606. PubMed ID: 22120195
    [Abstract] [Full Text] [Related]

  • 31. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.
    Bueno SM, González PA, Cautivo KM, Mora JE, Leiva ED, Tobar HE, Fennelly GJ, Eugenin EA, Jacobs WR, Riedel CA, Kalergis AM.
    Proc Natl Acad Sci U S A; 2008 Dec 30; 105(52):20822-7. PubMed ID: 19075247
    [Abstract] [Full Text] [Related]

  • 32. Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques.
    Patton K, Aslam S, Shambaugh C, Lin R, Heeke D, Frantz C, Zuo F, Esser MT, Paliard X, Lambert SL.
    Vaccine; 2015 Aug 26; 33(36):4472-8. PubMed ID: 26206269
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN, Bogaert L, Meek B, Zahn R, Vellinga J, Custers J, Serroyen J, Radošević K, Schuitemaker H.
    Vaccine; 2015 Oct 05; 33(41):5406-5414. PubMed ID: 26319741
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease.
    Boukhvalova MS, Prince GA, Soroush L, Harrigan DC, Vogel SN, Blanco JC.
    Vaccine; 2006 Jun 05; 24(23):5027-35. PubMed ID: 16675071
    [Abstract] [Full Text] [Related]

  • 39. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
    Cayatte C, Snell Bennett A, Rajani GM, Hostetler L, Maynard SK, Lazzaro M, McTamney P, Ren K, O'Day T, McCarthy MP, Schneider-Ohrum K.
    PLoS One; 2017 Jun 05; 12(11):e0188708. PubMed ID: 29182682
    [Abstract] [Full Text] [Related]

  • 40. Ginseng diminishes lung disease in mice immunized with formalin-inactivated respiratory syncytial virus after challenge by modulating host immune responses.
    Lee JS, Cho MK, Hwang HS, Ko EJ, Lee YN, Kwon YM, Kim MC, Kim KH, Lee YT, Jung YJ, Kang SM.
    J Interferon Cytokine Res; 2014 Nov 05; 34(11):902-14. PubMed ID: 25051168
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.